The Zacks Analyst Blog Highlights: Bristol-Myers, Honda, Danaher, MetLife And V.F.

For Immediate Release

Chicago, IL – Feb 26, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Bristol-Myers (NYSE:BMY) , Honda (NYSE:HMC) , Danaher (NYSE:DHR) , MetLife (NYSE:MET) and V.F. Corp. (NYSE:VFC) .

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Friday’s Analyst Blog:

Top Analyst Reports for Bristol-Myers, Honda and Danaher

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers, Honda and Danaher. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Bristol-Myers’ shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the last six months, gaining +13.4% vs. +4.4%. Bristol-Myers reported strong results for the fourth quarter beating on both earnings and sales. Strong sales of Opdivo and Eliquis contributed to the top line in the quarter.

In addition, the guidance for 2018 was encouraging. The Zacks analyst likes Bristol-Myers’ efforts to develop its pipeline, especially Opdivo. Several label expansion applications for Opdivo are under review in the United States and Europe. Potential approval will boost the prospects of these drugs. The positive results from the Checkmate-227 study for first-line treatment of lung cancer has already boosted prospects of approval.

However, pricing concerns, stiff competition in the HCV and immuno-oncology space are expected to remain an overhang on the company’s shares. Yervoy’s sales are expected to be under pressure due to the adoption of Opdivo in adjuvant melanoma.

(You can read the full research report on Bristol-Myers here >>>).

Shares of Honda have outperformed the Zacks Domestic Automotive industry over the last six months, increasing +28.1% vs. +21.5%. In third quarter of fiscal 2018 (ended Dec 31, 2017), Honda reported better-than-expected earnings. Revenues also came in higher than expectation. Through the Vision 2030 strategy plan, the company is focusing on strategies to boost coordination between research and development as well as procurement and manufacturing of its products.

The company is undertaking frequent collaborations to expand its business. The company has been recalling vehicles frequently over the last few years. Moreover, it has been facing a rise in R&D expenses and unfavorable foreign currency translation issues.

(You can read the full research report on Honda here >>>).

Danaher’s shares have gained +3.6% over the past three months, outperforming the Zacks Diversified Operations industry, which has declined -2.1% over the same period. Danaher kept its impressive earnings beat streak alive as its fourth-quarter 2017 adjusted earnings beat expectations.

The Zacks analyst is optimistic about the company’s core revenue and earnings growth, on the back of improving order trends and its operating culture, DBS. Its recent acquisitions – Pall and Cepheid – are proving to be strong profit churners, and will boost top-line growth as they become a part of the company’s core revenues.

However, slowdown in the company’s academic business in Europe and prolonged sluggishness in the Dental business might restrict growth, going forward. Moreover, weakness in industrial markets and stiff competition may also hurt the company's financials.

This apart, the company remains highly vulnerable to adverse foreign currency translations, as a significant portion of its revenues is derived from regions outside the United States.

(You can read the full research report on Danaher here >>>).

Other noteworthy reports we are featuring today include MetLife and V.F. Corp.

Zacks Top 10 Stocks for 2018

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?

Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp (NYSE:FMC). and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.

Access Zacks Top 10 Stocks for 2018 today >>

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook (NASDAQ:FB): https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.